NLS Pharma - Prakiraan wutah bathi resik saben saham kanggo taun ngarep NLSP

The digitalization of clinical data analysis at NLS Pharmaceutics AG (NLSP) accelerates hypothesis testing, confirming the consensus on next year's earnings per share, where the 0.00 mark reflects the latest data. The development of treatments for ADHD and sleep disorders minimizes regulatory capital risks. Simultaneously, the company is modernizing its laboratory capacities by implementing automated control within clean booths.

NLS Pharma (NLSP): Prakiraan wutah bathi resik saben saham kanggo taun ngarep saka 04.07.2022 nganti 31.10.2025

Ringkesan rincian data analitis NLS Pharmaceutics AG (NLSP)

- rega lan prakiraan konsensus rega:

Bagan rega nlspharma.com|NLSP - Konsensus nilai wajar

- rincian nilai pasar emiten:

Nilai pasar NLS Pharmaceutics|NLSP - Total Nilai Perusahaan

- rincian nilai buku perusahaan:

Aset Bersih saben Siji Saham NLS Pharmaceutics|NLSP - Nilai Buku Perusahaan|Rasio Nilai Pasar marang Nilai Buku nlspharma.com|NLSP - Aset Perusahaan

- indikator beban kredit lan likuiditas emiten:

Total Utang marang Modal NLS Pharmaceutics AG|NLSP - Tanggungan utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas NLS Pharmaceutics Ltd.|NLSP - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku NLS Pharmaceutics|NLSP - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan NLS Pharmaceutics|Likuiditas cepet nlspharma.com

- data bathi resik lan rasio valuasi:

NLSP - Asil keuangan resik|Bathi mangsa ngarep NLS Pharmaceutics AG|NLSP - Nilai perusahaan marang bathi resik|Rega marang bathi mangsa ngarep NLS Pharma|NLSP - Rasio kapitalisasi marang bathi lan wutah|Pangali EV/EBITDA NLS Pharma|NLSP - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) NLS Pharmaceutics|NLSP - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan nlspharma.com|NLSP - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep NLS Pharmaceutics AG

- statistik dodolan lan pendapatan perusahaan:

NLSP - Dodolan perusahaan|Prakiraan volume dodolan NLS Pharma|NLSP - Multiplikator P/S|Multiplikator Forward P/S NLS Pharma

Analisis fundamental perusahaan:NLSP, NLS Pharma

This indicator measures the consensus forecast for earnings changes over the coming year, reflecting the speed at which the market re-evaluates business value through expected EPS dynamics. By analyzing the valuation of forward net income growth rates, an investor can gauge the asset's sensitivity to the clinical successes of NLS Pharmaceutics AG (NLSP), where the binary risk of sleep disorder drug development determines the company's entire future profitability.

Perusahaan pesaing